Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Investor Presentation (September 2019)
14 slides from Oncoinvent Asa's investor presentation, September 2019
Slide 1: Oncoinvent
On~o Invent Jan A. Alfheim CEO
Slide 2: Oncoinvent AS
Oncoinvent AS • Founded in 2010 • Lead candidate Radspherin® expected to enter clinical phase in 2019 for treatment of Peritoneal carcinomatosis • 3rd company started by serial entrepreneurs Dr. Roy H. Larsen, Ph.D. Dr. Roy H. Larsen and Professor Øyvind S. Bruland • 19 fulltime employees, 3 Industr
Slide 3: Radspherin: alpha-emitting microparticles for local applications
Radspherin® alpha-emitting microparticles for local applications A NEW alpha-emitting radioisotope • High energetic radiation for efficient tumor cell kill • Local deposition of radiation • Therapeutic relevant temporal and spatial window • Low probability of unintended radiation damage SPECIALLY DE
Slide 4: GMP certified manufacturing premises
GMP certified manufacturing premises • 2 Class B-isotope production suites for Ra-224 and Radspherin® • isotope storage room • quality control room • packaging & shipping room • a Grade B clean room production suite for particle production • a Class B-isotope research lab • a general research lab 4
Slide 5: Peritoneal carcinomatosis
Peritoneal carcinomatosis Peritoneal carcinomatosis (PC) is a metastatic cancer within the abdominal cavity frequently occurring in several primary cancers such as: • 70 % of patients with ovarian cancer • 32 % of patients with colorectal cancer Malignant ascites is a serious condition • 10 % of pat
Slide 6: Peritoneal carcinomatosis in ovarian cancer patients
Peritoneal carcinomatosis in ovarian cancer patients 5 year survival rates in ovarian cancer* The vast majority of ovarian cancer patients are diagnosed at stage 3 & 4 * (presence of metastatic disease) and 90% 70% do not survive beyond 5 years 39% 17% 1 2 3 4 Stage of disease * source: http://www.c
Slide 7: Peritoneal carcinomatosis in colorectal cancer patients
Peritoneal carcinomatosis in colorectal cancer patients Long-term survival of patients with peritoneal carcinomatosis of colorectal origin The majority of colorectal cancer * patients with peritoneal carcinomatosis 78% do not survive beyond 5 years 36% 24% 1 year 3 years 5 years * source: https://ww
Slide 8: Incidence of PC
Incidence of PC Ovarian cancer Yearly incidence Mortality • EU 44 150 29 800 • USA 22 300 14 200 • World-wide: 200 000 125 000 70% with metastasis in the peritoneum Other indications, EU + USA Yearly incidence Incidence of peritoneal carcinomatosis Stomach cancer 107 000 10 % Colorectal cancer 477 7
Slide 9: Standard treatment of peritoneal carcinomatosis
Standard treatment of peritoneal carcinomatosis Multimodality therapy consisting of: • Cytoreductive surgery (CRS) • Intravenous adjuvant chemotherapy • Intraperitoneal chemotherapy • Hyperthermic Intraperitoneal Chemotherapy (HIPEC) 9
Slide 10: Pre-clinical data: Radspherin vs Pb-212 RIT
Pre-clinical data: Radspherin vs Pb-212 RIT ES-2 model treated with Radspherin Kasten et al., 2017: ES-2 model treated with Pb-212-F3-C25 Ab radioimmunotherapy untreated (filled circles) MS: 15 days 16,5 MBq/kg (filled diamonds) MS: 28 days 8.5 MBq/kg (filled squares) MS: 32 days 17.5 MBq/kg (filled
Slide 11: Pre-clinical data: Biodistribution of free Ra-224 versus labelled microparticles
Pre-clinical data: Biodistribution of free Ra-224 versus Ra- 224 labelled microparticles Biodistribution after interperitoneal administration in mice without tumor 11
Slide 12: Collaboration partner: The Norwegian Radium Hospital
Oncoinvent collaboration partner: The Norwegian Radium Hospital • Part of the Oslo University Hospital dedicated to cancer treatment • Have contributed with a technical platform and research competence for pre- clinical testing of Radspherin® • Stein Gunnar Larsen, MD, PhD, Head of dept. Norwegian N
Slide 13: Collaboration partner: University Hospitals Leuven, Belgium
Oncoinvent collaboration partner: University Hospitals Leuven, Belgium Dr. Ignace Vergote, MD PhD FACS FSPS Chairman, University Hospitals Leuven, 13
Slide 14: Innovations for better cancer care
Innovations for better cancer care Thank you for your attention